NICE guidance on bevacizumab in combination with gemcitabine and carboplatin for treating the first recurrence of platinum-sensitive advanced ovarian cancer.

Pinilla-Dominguez, Pilar

NICE guidance on bevacizumab in combination with gemcitabine and carboplatin for treating the first recurrence of platinum-sensitive advanced ovarian cancer. [electronic resource] - The Lancet. Oncology Jul 2013 - 691-2 p. digital

Publication Type: News

1474-5488

10.1016/S1470-2045(13)70247-X doi


Antibodies, Monoclonal, Humanized--administration & dosage
Antineoplastic Combined Chemotherapy Protocols--economics
Bevacizumab
Carboplatin--administration & dosage
Cost-Benefit Analysis
Deoxycytidine--administration & dosage
Drug Costs
Female
Humans
Neoplasm Recurrence, Local--drug therapy
Ovarian Neoplasms--drug therapy
Practice Guidelines as Topic
Quality-Adjusted Life Years
Survival Analysis
Time Factors
Treatment Outcome
Gemcitabine